Orbit management sans exenteration with retrobulbar injection of amphotericin-B in Rhinoorbitocerebral mucormycosis: Impact on survival

PurposeThis study aims to describe the impact on survival of non-exenteration management of orbital disease, supplemented with transcutaneous retrobulbar injection of amphotericin B (TRAMB), in a cohort of patients with COVID-19-associated ROCM, a life-threatening condition for which exenteration is generally the preferred treatment modality.<b>Method</b>: This retrospective cohort study included 69 COVID-19-associated ROCM patients. All patients were treated with intravenous liposomal amphotericin-B and surgical debridement of paranasal sinuses. All patients with orbital disease were treated with TRAMB (42/69); orbital debridement or extended enucleation was performed when the disease was severe or progressive; debridement of intracranial disease was done when indicated.ResultsOf the 69 patients included, at discharge, 45/69(65.2%) had cured/stable ROCM, 13/69(18.8%) died and 11/69(15.94%) were discharged on request, with progressive disease. The vision was preserved in 45/69(65%), a blind eye with preserved ocular globe in 18/69(26%), and 6/69(9%) underwent extended enucleation. At 18 months follow-up, 6/56 died, 13/56 were lost to follow-up and 37/56 were alive. The cumulative mortality was 27% (19/69). Independent risk factors for mortality were increasing age(<i>p</i> = 0.003), diabetic ketoacidosis(<i>p</i> = 0.006), severe COVID-19 (<i>p</i> = 0.04), and CNS involvement (<i>p</i> = 0.01).ConclusionIn this study, conservative orbit management sans exenteration augmented with retrobulbar injection of amphotericin B was an effective treatment modality for orbital involvement in ROCM. The mortality in our patients was comparable to reports where exenteration was the first line of treatment, with better vision and cosmetic outcomes. Further studies comparing orbit conservation with TRAMB versus exenteration may be needed to delineate further, whether this approach can be an alternative to exenteration.

Authors

Institutions

Publication Details

Journal
European Journal of Ophthalmology
Published
2025-07-30
DOI
https://doi.org/10.1177/11206721251361276
Citations
1
Primary Topic
Sinusitis and nasal conditions
Type
article
Field-Weighted Citation Impact
1.85
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Orbit management sans exenteration with retrobulbar injection of amphotericin-B in Rhinoorbitocerebral mucormycosis: Impact on survival

Shubashree Karat, Anita Ross, Aaron Charles Lobo, Thenmozhi Nagarajan et al.
1 citations
European Journal of Ophthalmology
Sinusitis and nasal conditions
1.85
article

Orbit management sans exenteration with retrobulbar injection of amphotericin-B in Rhinoorbitocerebral mucormycosis: Impact on survival

Shubashree Karat, Anita Ross, Aaron Charles Lobo, Thenmozhi Nagarajan, Suneetha Nithyanandam, Philip Abraham
article en
1 citations

Abstract

PurposeThis study aims to describe the impact on survival of non-exenteration management of orbital disease, supplemented with transcutaneous retrobulbar injection of amphotericin B (TRAMB), in a cohort of patients with COVID-19-associated ROCM, a life-threatening condition for which exenteration is generally the preferred treatment modality.<b>Method</b>: This retrospective cohort study included 69 COVID-19-associated ROCM patients. All patients were treated with intravenous liposomal amphotericin-B and surgical debridement of paranasal sinuses. All patients with orbital disease were treated with TRAMB (42/69); orbital debridement or extended enucleation was performed when the disease was severe or progressive; debridement of intracranial disease was done when indicated.ResultsOf the 69 patients included, at discharge, 45/69(65.2%) had cured/stable ROCM, 13/69(18.8%) died and 11/69(15.94%) were discharged on request, with progressive disease. The vision was preserved in 45/69(65%), a blind eye with preserved ocular globe in 18/69(26%), and 6/69(9%) underwent extended enucleation. At 18 months follow-up, 6/56 died, 13/56 were lost to follow-up and 37/56 were alive. The cumulative mortality was 27% (19/69). Independent risk factors for mortality were increasing age(<i>p</i> = 0.003), diabetic ketoacidosis(<i>p</i> = 0.006), severe COVID-19 (<i>p</i> = 0.04), and CNS involvement (<i>p</i> = 0.01).ConclusionIn this study, conservative orbit management sans exenteration augmented with retrobulbar injection of amphotericin B was an effective treatment modality for orbital involvement in ROCM. The mortality in our patients was comparable to reports where exenteration was the first line of treatment, with better vision and cosmetic outcomes. Further studies comparing orbit conservation with TRAMB versus exenteration may be needed to delineate further, whether this approach can be an alternative to exenteration.

European Journal of OphthalmologyVol. 36(1)
St. John's School (US), St.John's Medical College Hospital (IN)
Good health and well-being
Openalex Percentile: Top 13%
Sinusitis and nasal conditions
1.85
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.